Premium
Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase
Author(s) -
Panetta John C.,
Liu Yiwei,
Swanson Hope D.,
Karol Seth E.,
Pui ChingHon,
Inaba Hiroto,
Jeha Sima,
Relling Mary V.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28244
Subject(s) - medicine , dosing , lymphoblastic leukemia , asparaginase , anesthesia , gastroenterology , leukemia
It is unclear if dosing intervals for Erwinase can be extended with intramuscular (i.m.) versus intravenous (i.v.) dosing. Children with acute lymphoblastic leukemia received Erwinase at 30 000‐42 000 IU/m 2 i.v. or i.m. I.m. Erwinase ( n = 22) achieved activity above 0.1 IU/mL for longer than i.v. Erwinase ( n = 33) (3.4 vs 2.9 days, P = 0.0007). With 30 000 IU/m 2 Monday, Wednesday, Friday, more patients achieved adequate concentrations over the weekend with i.m. vs i.v. dosing ( P = 5 × 10 −36 ). A schedule with i.v. doses on Monday and Wednesday and i.m. doses on Friday of 30 000 IU/m 2 maintained activity > 0.1 IU/mL over the weekend in 80% of patients.